Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 134

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 134
---
 to such litigation and consider in good faith Kaken’s advice with respect to such litigation,
subject to certain limitations specified in the Divestiture Agreement.

Wrong Pockets

Following the completion of the Divestiture, if Aadi or any of its affiliates receive, or become aware that Aadi or any of its affiliates own or possess, any
assets, rights, properties, notices, monies or amounts that are used or held for use in the FYARRO Business (and the treatment of which is not otherwise separately contemplated by the terms of the Divestiture Agreement or the Transition Services
Agreement), or are otherwise properly due, deliverable or owing to Kaken or Aadi Sub, then Aadi will, for no additional consideration, promptly sell, convey, transfer, assign and deliver such assets, rights, properties, notices, monies or amounts to
Kaken or its affiliates as Kaken may designate.

Following the completion of the Divestiture, if Kaken or any of its affiliates receive, or become aware
that Kaken or any of its affiliates (including Aadi Sub) own or possess, any assets, rights, properties, notices, monies or amounts that are properly due, deliverable or owing to Aadi, Kaken will, for no additional consideration, promptly sell,
convey, transfer, assign and deliver such assets, rights, properties, notices, monies or amounts to Aadi or its affiliates as Aadi may designate.

Pre-Closing Restructuring

Subject to the terms of the Divestiture Agreement, Aadi has agreed to use its reasonable best efforts to cause certain
pre-closing transactions to be consummated to ensure the complete transfer of all assets and agreements relating to the FYARRO Business from Aadi to Aadi Sub. Aadi has agreed to provide Kaken reasonable opportunity to review drafts of the agreements
to be entered into in connection with the Pre-Closing Restructuring and to consider in good faith any reasonable comments timely submitted by Kaken with respect to such agreements.

Clinical Trial Wind Down

Subject to certain limitations
and conditions set forth in the Divestiture Agreement, Aadi has agreed that it will be financially responsible for the full costs and expenses associated with the wind down of the PRECISION-1 Clinical Trial until the earlier of one year from the
date of completion of the Divestiture for the current FDA expanded access program and upon completion of the FDA expanded access program in accordance with the current protocol, and that it would promptly reimburse